Bridging the Gap in Pancreatic Imaging: A New Era of AI-Powered Precision [0.03%]
胰腺影像的精准医疗时代：人工智能搭桥换代工程
Ulas Bagci,Gorkem Durak
Ulas Bagci
Muhammad Wasif Saif
Muhammad Wasif Saif
Introduction: Pancreatic adenocarcinoma is a devastating malignancy, associated with a grim prognosis, due to its silent presentation and lack of diagnostic tests. In addition, treatment options are limited to few agents,...
Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer [0.03%]
胰腺癌患者的术后放疗的生存收益及其不平等现象
Mirza Zain Baig,Alexandra Filkins,Muhammad Khan et al.
Mirza Zain Baig et al.
Background: The effects of adjuvant radiation therapy on pancreatic cancer outcomes after resection are not well defined in the literature. Methods: ...
Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9? [0.03%]
术后CA19-9升高的胰腺癌患者在手术后辅助化疗后维持化疗是否有生存益处？
Muhammad Wasif Saif,Melissa H Smith,Martin D Goodman et al.
Muhammad Wasif Saif et al.
Background: Pancreatectomy offers only potential for cure but is only possible in a minority of patients. Even in those patients who receive adjuvant chemotherapy, majority of them succumb to death due to metastases. Radi...
New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020 [0.03%]
2020年5月29-31日第44届ASCO年度虚拟会议要点：胰腺癌治疗的新进展
Muhammad Wasif Saif
Muhammad Wasif Saif
Pancreatic cancer has the worst survival of any solid tumor. Overall, pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. The American Cancer Society's estimates that 57,600 people (30,400 men...
Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat? [0.03%]
2019冠状病毒病大流行下的胰腺癌管理：治疗与否？
Rajvi Patel,Muhammad Wasif Saif
Rajvi Patel
Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dil...
Does Neoadjuvant Therapy Improve Outcome in Resectable PC? Gastrointestinal Cancers Symposium 2019 [0.03%]
新辅助治疗可以改善可切除胰腺癌患者的预后吗？-2019年胃肠道癌症研讨会摘要回顾
Maged Ghaly,Muhammad Wasif Saif
Maged Ghaly
Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary Tumors [0.03%]
作为转移性原发不明癌症（CUP），疑似胰胆肿瘤的一线治疗的简化的/同期(S)GOLF治疗
Muhammad Wasif Saif,Komal Wasif,Martin D Goodman et al.
Muhammad Wasif Saif et al.
Background: Carcinoma of unknown primary represents a therapeutic challenge in oncological practice. Evidence lacks to support particular chemotherapy selection and empirical therapies are commonly extrapolated from data ...
Gregory T Brennan,Muhammad Wasif Saif
Gregory T Brennan
Pancreatic enzyme replacement therapy is safe and effective at treating pancreatic exocrine insufficiency. There are multiple causes of pancreatic exocrine insufficiency including chronic pancreatitis, cystic fibrosis and pancreatic cancer....
Comparable Responses in Male and Female Mice to Cerulein-Induced Chronic Pancreatic Injury and Recovery [0.03%]
通过反复诱导分析小鼠慢性胰腺损伤后的性别差异及恢复过程中的胰腺适应性反应
Tolulope F Obafemi,Peter Yu,Jing Li et al.
Tolulope F Obafemi et al.
Objective: The cerulein-induced mouse pancreatitis model is a well-established, commonly used representation of human chronic pancreatitis pathology. Although studies report sex-dependent differences in human chronic panc...